Prostate cancer in men using testosterone supplementation

Franklin D. Gaylis, Daniel W. Lin, Jeffrey M. Ignatoff, Christopher Amling, Ronald F. Tutrone, Daniel J. Cosgrove

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: Although an association between testosterone supplementation and the development of prostate cancer is unproven, a recent increase in the use of this therapy has reopened the debate about its safety in men at risk for prostate cancer. To increase awareness of this risk, we report on a series of patients in whom clinically significant prostate cancer developed and was presumed to be related to exogenous testosterone use. Materials and Methods: The medical records of 6 urology practices were reviewed to identify men undergoing testosterone supplementation for sexual dysfunction or "rejuvenation" who were found to have prostate cancer after initiation of exogenous testosterone supplementation. Cases were analyzed to determine clinical and pathological parameters characterizing the presentation of prostate cancer. Results: A total of 20 men were diagnosed with prostate cancer after initiation of testosterone therapy. Prostate cancer was detected within 2 years of testosterone initiation in 11 men (55%) and from 28 months to 8 years in the remainder. The tumors were of moderate and high grade, being Gleason sum 6, 7 and 8 to 10 in 9 (45%), 6 (30%) and 5 (25%) men, respectively. Median serum prostate specific antigen (PSA) concentration at diagnosis tended to be low at 5.1 ng/ml (range 1.1 to 329.0) and digital rectal examination generally proved more sensitive than PSA assays in detecting the cancer. Patients seen by nonurologist physicians were monitored less often for prostate cancer during testosterone use than those followed by urologists. Conclusions: Prostate cancer may become clinically apparent within months to a few years after the initiation of testosterone treatment. Digital rectal examination is particularly important in the detection of these cancers. Physicians prescribing testosterone supplementation and patients receiving it should be cognizant of this risk, and serum PSA testing and digital rectal examination should be performed frequently during treatment.

Original languageEnglish (US)
Pages (from-to)534-538
Number of pages5
JournalJournal of Urology
Volume174
Issue number2
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Testosterone
Prostatic Neoplasms
Digital Rectal Examination
Prostate-Specific Antigen
Physicians
Rejuvenation
Neoplasms
Urology
Therapeutics
Serum
Medical Records
Safety

Keywords

  • Diagnosis
  • Hypogonadism
  • Prostate-Specific Antigen
  • Prostatic neoplasms
  • Testosterone

ASJC Scopus subject areas

  • Urology

Cite this

Gaylis, F. D., Lin, D. W., Ignatoff, J. M., Amling, C., Tutrone, R. F., & Cosgrove, D. J. (2005). Prostate cancer in men using testosterone supplementation. Journal of Urology, 174(2), 534-538. https://doi.org/10.1097/01.ju.0000165166.36280.60

Prostate cancer in men using testosterone supplementation. / Gaylis, Franklin D.; Lin, Daniel W.; Ignatoff, Jeffrey M.; Amling, Christopher; Tutrone, Ronald F.; Cosgrove, Daniel J.

In: Journal of Urology, Vol. 174, No. 2, 08.2005, p. 534-538.

Research output: Contribution to journalArticle

Gaylis, FD, Lin, DW, Ignatoff, JM, Amling, C, Tutrone, RF & Cosgrove, DJ 2005, 'Prostate cancer in men using testosterone supplementation', Journal of Urology, vol. 174, no. 2, pp. 534-538. https://doi.org/10.1097/01.ju.0000165166.36280.60
Gaylis, Franklin D. ; Lin, Daniel W. ; Ignatoff, Jeffrey M. ; Amling, Christopher ; Tutrone, Ronald F. ; Cosgrove, Daniel J. / Prostate cancer in men using testosterone supplementation. In: Journal of Urology. 2005 ; Vol. 174, No. 2. pp. 534-538.
@article{97a67d62ffbf4bea99bd684c64811d47,
title = "Prostate cancer in men using testosterone supplementation",
abstract = "Purpose: Although an association between testosterone supplementation and the development of prostate cancer is unproven, a recent increase in the use of this therapy has reopened the debate about its safety in men at risk for prostate cancer. To increase awareness of this risk, we report on a series of patients in whom clinically significant prostate cancer developed and was presumed to be related to exogenous testosterone use. Materials and Methods: The medical records of 6 urology practices were reviewed to identify men undergoing testosterone supplementation for sexual dysfunction or {"}rejuvenation{"} who were found to have prostate cancer after initiation of exogenous testosterone supplementation. Cases were analyzed to determine clinical and pathological parameters characterizing the presentation of prostate cancer. Results: A total of 20 men were diagnosed with prostate cancer after initiation of testosterone therapy. Prostate cancer was detected within 2 years of testosterone initiation in 11 men (55{\%}) and from 28 months to 8 years in the remainder. The tumors were of moderate and high grade, being Gleason sum 6, 7 and 8 to 10 in 9 (45{\%}), 6 (30{\%}) and 5 (25{\%}) men, respectively. Median serum prostate specific antigen (PSA) concentration at diagnosis tended to be low at 5.1 ng/ml (range 1.1 to 329.0) and digital rectal examination generally proved more sensitive than PSA assays in detecting the cancer. Patients seen by nonurologist physicians were monitored less often for prostate cancer during testosterone use than those followed by urologists. Conclusions: Prostate cancer may become clinically apparent within months to a few years after the initiation of testosterone treatment. Digital rectal examination is particularly important in the detection of these cancers. Physicians prescribing testosterone supplementation and patients receiving it should be cognizant of this risk, and serum PSA testing and digital rectal examination should be performed frequently during treatment.",
keywords = "Diagnosis, Hypogonadism, Prostate-Specific Antigen, Prostatic neoplasms, Testosterone",
author = "Gaylis, {Franklin D.} and Lin, {Daniel W.} and Ignatoff, {Jeffrey M.} and Christopher Amling and Tutrone, {Ronald F.} and Cosgrove, {Daniel J.}",
year = "2005",
month = "8",
doi = "10.1097/01.ju.0000165166.36280.60",
language = "English (US)",
volume = "174",
pages = "534--538",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Prostate cancer in men using testosterone supplementation

AU - Gaylis, Franklin D.

AU - Lin, Daniel W.

AU - Ignatoff, Jeffrey M.

AU - Amling, Christopher

AU - Tutrone, Ronald F.

AU - Cosgrove, Daniel J.

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: Although an association between testosterone supplementation and the development of prostate cancer is unproven, a recent increase in the use of this therapy has reopened the debate about its safety in men at risk for prostate cancer. To increase awareness of this risk, we report on a series of patients in whom clinically significant prostate cancer developed and was presumed to be related to exogenous testosterone use. Materials and Methods: The medical records of 6 urology practices were reviewed to identify men undergoing testosterone supplementation for sexual dysfunction or "rejuvenation" who were found to have prostate cancer after initiation of exogenous testosterone supplementation. Cases were analyzed to determine clinical and pathological parameters characterizing the presentation of prostate cancer. Results: A total of 20 men were diagnosed with prostate cancer after initiation of testosterone therapy. Prostate cancer was detected within 2 years of testosterone initiation in 11 men (55%) and from 28 months to 8 years in the remainder. The tumors were of moderate and high grade, being Gleason sum 6, 7 and 8 to 10 in 9 (45%), 6 (30%) and 5 (25%) men, respectively. Median serum prostate specific antigen (PSA) concentration at diagnosis tended to be low at 5.1 ng/ml (range 1.1 to 329.0) and digital rectal examination generally proved more sensitive than PSA assays in detecting the cancer. Patients seen by nonurologist physicians were monitored less often for prostate cancer during testosterone use than those followed by urologists. Conclusions: Prostate cancer may become clinically apparent within months to a few years after the initiation of testosterone treatment. Digital rectal examination is particularly important in the detection of these cancers. Physicians prescribing testosterone supplementation and patients receiving it should be cognizant of this risk, and serum PSA testing and digital rectal examination should be performed frequently during treatment.

AB - Purpose: Although an association between testosterone supplementation and the development of prostate cancer is unproven, a recent increase in the use of this therapy has reopened the debate about its safety in men at risk for prostate cancer. To increase awareness of this risk, we report on a series of patients in whom clinically significant prostate cancer developed and was presumed to be related to exogenous testosterone use. Materials and Methods: The medical records of 6 urology practices were reviewed to identify men undergoing testosterone supplementation for sexual dysfunction or "rejuvenation" who were found to have prostate cancer after initiation of exogenous testosterone supplementation. Cases were analyzed to determine clinical and pathological parameters characterizing the presentation of prostate cancer. Results: A total of 20 men were diagnosed with prostate cancer after initiation of testosterone therapy. Prostate cancer was detected within 2 years of testosterone initiation in 11 men (55%) and from 28 months to 8 years in the remainder. The tumors were of moderate and high grade, being Gleason sum 6, 7 and 8 to 10 in 9 (45%), 6 (30%) and 5 (25%) men, respectively. Median serum prostate specific antigen (PSA) concentration at diagnosis tended to be low at 5.1 ng/ml (range 1.1 to 329.0) and digital rectal examination generally proved more sensitive than PSA assays in detecting the cancer. Patients seen by nonurologist physicians were monitored less often for prostate cancer during testosterone use than those followed by urologists. Conclusions: Prostate cancer may become clinically apparent within months to a few years after the initiation of testosterone treatment. Digital rectal examination is particularly important in the detection of these cancers. Physicians prescribing testosterone supplementation and patients receiving it should be cognizant of this risk, and serum PSA testing and digital rectal examination should be performed frequently during treatment.

KW - Diagnosis

KW - Hypogonadism

KW - Prostate-Specific Antigen

KW - Prostatic neoplasms

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=22144488457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144488457&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000165166.36280.60

DO - 10.1097/01.ju.0000165166.36280.60

M3 - Article

C2 - 16006887

AN - SCOPUS:22144488457

VL - 174

SP - 534

EP - 538

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -